Pfizer Ltd, the Indian subsidiary of the world’s largest drug maker Pfizer Inc., is making an aggressive play in the Indian generics or off-patent drugs market. The generic portfolio will boost its revenue once it succeeds in semi-urban and rural markets. It has already launched a widely prescribed hypertension drug Telmisartan under the brand name Targit, and will launch at least three more generics by December. Telmisartan is currently marketed by at least 20 domestic drug makers, including Glenmark Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Ltd, and Ranbaxy Laboratories Ltd.
Pfizer Ltd is the 12th largest pharma company in the country by sales revenue and has expanded its field force by 220 people over the past few months for this business and identified several top-selling Indian generic drugs of which it will launch versions. The drugs in the project would address both chronic and infectious diseases. The project will see the company challenging local rivals such as Ranbaxy, Cipla, Sun Pharma, Piramal Healthcare Ltd, among others, whose primary business comes from generics. It is also a radical shift for Pfizer from its traditional business model of being an original and speciality pharmaceuticals manufacturer.
Generics represent one of the fastest growth segments in the global pharmaceuticals market as costs and access are its primary drivers of growth. The Indian pharma market, driven largely by generics, has been growing at 14-15% over the past four years. Pfizer grew by 12% in 2008 and ended the year with revenue of Rs704 crore. The company follows a December-November fiscal year.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.75 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 940.00 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: